Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172145
Title: Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
Author: Sanjosé Llongueras, Silvia de
Serrano, Beatriz
Tous, Sara
Alejo, Maria
Lloveras, Belén
Quirós, Beatriz
Clavero, Omar
Vidal-Bel, August
Ferrándiz Pulido, Carla
Pavón Ribas, Miquel Àngel
Holzinger, Dana
Halec, Gordana
Tommasino, Massimo
Quint, Wim
Pawlita, Michael
Muñoz, Nubia
Bosch José, Francesc Xavier, 1947-
Alemany i Vilches, Laia
RIS HPV TT, VVAP and Head and Neck study groups
Keywords: Papil·lomavirus
Càncer de coll uterí
Papillomaviruses
Cervix cancer
Issue Date: 1-Nov-2018
Publisher: Oxford University Press
Abstract: Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Note: Reproducció del document publicat a: https://doi.org/10.1093/jncics/pky045
It is part of: JNCI Cancer Spectrum, 2018, vol. 2, num. 4, p. pky045
URI: http://hdl.handle.net/2445/172145
Related resource: https://doi.org/10.1093/jncics/pky045
ISSN: 2515-5091
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
683951.pdf2.97 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons